Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas.
Phase of Trial: Phase IV
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Nerve sheath neoplasms
- Focus Pharmacokinetics
- 27 Feb 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.
- 28 Jan 2016 Planned End Date changed from 31 Dec 2015 to 31 Dec 2016, as reported by United Kingdom Clinical Research Network record
- 21 Aug 2014 Planned End Date changed from 31 Jul 2014 to 31 Jul 2015 according to United Kingdom Clinical Research Network record.